Table 5.
Pharmacokinetic parameters of daidzein obtained from 11 subjects receiving a single oral administration of soy milk (SOY Phase) and a short-course oral ciprofloxacin followed by a single oral administration of soy milk (CIPRO/SOY phase).
| Pharmacokinetic parameters | Daidzein | |||
|---|---|---|---|---|
| SOY phase | CIPRO/SOY phase | |||
| Mean±SD | Median (IQR) | Mean±SD | Median (IQR) | |
| Cmax (ng/mL) | 833.12±351.17 | 752.60 (298.52) | 511.17±243.74∗ | 497.19 (323.01)∗∗ |
| Tmax (h) | 6.36±1.21 | 6.00 (1.00) | 6.55±1.29 | 6.00 (2.00) |
| AUC0-t (ng.h/mL) | 8553.84±5424.86 | 6826.87 (5759.28) | 5977.10±4256.78∗ | 5599.80 (4391.67)∗∗ |
| AUC0-∞ (ng.h/mL) | 9431.94±5411.69 | 7254.24 (4777.05) | 6746.22±4403.37∗ | 6003.36 (4164.71)∗∗ |
| t1/2 (h) | 6.52±1.89 | 6.23 (1.64) | 6.42±2.07 | 6.36 (1.45) |
Data represent mean±SD and median (interquartile range, IQR). ∗p <0.05 versus SOY phase using a paired t-test. ∗∗p <0.05 versus SOY phase using Wilcoxon's signed-rank test.